A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)

Inclusion Criteria: * Is able to read and sign a consent form; * Is from ≥18 to \<90 years of age; * Has diarrhea, at least 3 times during one day, or 200 mL or liquid stool if using a rectal device; * Tests positive for Clostridium difficile; * If female, must not be pregnant or nursing and take appropriate measures to not get pregnant during the study. Exclusion Criteria: * Has toxic megacolon and/or known small bowel ileus; * Has received treatment with intravenous immune globulin (IVIG) within the past 30 days; * Has received treatment with a fecal transplant within 7 days, and/or if the doctor anticipates to give the participant a fecal transplant during the study; * Has received a certain amount of antibacterial therapy specific for current CDAD, unless it is not working; * Has received an investigational vaccine against Clostridium difficile; * Has received an investigational product containing monoclonal antibodies against toxin A or B within 180 days; * Has more than 2 episodes of CDAD within 90 days; * Has had major gastrointestinal (GI) surgery (i.e. significant bowel resection) within 3 months (this does not include appendectomy or cholecystectomy); * Has a history of prior inflammatory bowel disease: ulcerative colitis, Crohn's disease, or microscopic colitis; * Is unable to discontinue loperamide, diphenoxylate/atropine, or cholestyramine during the duration of the study; * Is unable to discontinue opiate treatment unless on a stable dose; * Has known positiv…